RxDoctor Payments Data

Nicki Peters, NP

Family · Meridian, IDNPI 1871644583

Payments from drug & device makers

$672in general payments, 2019–2025

Across 25 payments — averaging $26.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$226
  • Axsome Therapeutics, Inc.$144
  • Takeda Pharmaceuticals U.S.A., Inc.$125
  • Corium, LLC$78
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$60
  • Alkermes, Inc.$19
  • plus $18 from 1 others

What the payments were for

  • Food & beverage$672100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$672 in reported general payments places this provider in the 65th percentile of 809 family providers in Idaho.

See all family providers in Idaho

Medicare billing

Part B allowed, 2024
$7,308
Medicare patients
17
Services billed
73

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl21$43,946
Buspirone Hcl66$2,623
Lamotrigine74$1,487
Dexmethylphenidate Hcl23$1,453
Zolpidem Tartrate ErZolpidem Tartrate28$1,008
Quetiapine Fumarate33$721
Desvenlafaxine Succinate ErDesvenlafaxine Succinate13$698
Guanfacine Hcl ErGuanfacine Hcl15$548
Trazodone Hcl41$502
Gabapentin30$461
Bupropion XlBupropion Hcl20$440
Sertraline Hcl28$361
Mirtazapine16$335
Propranolol Hcl19$269
Dextroamphetamine Sulfate12$257

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$226$43,94621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 809 family providers in Idaho.

Other family in Meridian

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →